Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

mAbs

Showing results (131-140 of 1,833) with videos related to

Pageof 184
Sort By:
Mabs|February 20, 2015
Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokineticsAmita Datta-Mannan, Arunkumar Thangaraju, Donmienne Leung, et al.
Mabs|February 19, 2015
Monoclonal antibodies specific to human Δ42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesisLin Cheng, Xian Tang, Li Liu, et al.
Mabs|May 10, 2023
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptorsKerry A Whalen, Kavya Rakhra, Naveen K Mehta, et al.
Mabs|April 9, 2021
Calculation of therapeutic antibody viscosity with coarse-grained models, hydrodynamic calculations and machine learning-based parametersPin-Kuang Lai, James W Swan, Bernhardt L Trout
Mabs|July 14, 2020
Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chainJoschka Bauer, Sven Mathias, Sebastian Kube, et al.
Mabs|April 26, 2021
A platform-agnostic, function first-based antibody discovery strategy using plasmid-free mammalian expression of antibodiesRuijun Zhang, Ponraj Prabakaran, Xiaocong Yu, et al.
Mabs|April 27, 2021
N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stabilityMin Ji Ko, Daehae Song, Juhee Kim, et al.
Mabs|May 15, 2023
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasisSusanne Klint, Joachim Feldwisch, Lindvi Gudmundsdotter, et al.
Mabs|April 26, 2012
Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface displayChristian Votsmeier, Hanna Plittersdorf, Oliver Hesse, et al.
Mabs|April 26, 2012
Monoclonal antibodies: longitudinal prescribing information analysis of hypersensitivity reactionsKonstantin Kleyman, Debra S Weintraub
Pageof 184

Showing results (131-140 of 1,833) with videos related to

Sort By:
Pageof 184
Mabs|February 20, 2015
Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokineticsAmita Datta-Mannan, Arunkumar Thangaraju, Donmienne Leung, et al.
Mabs|February 19, 2015
Monoclonal antibodies specific to human Δ42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesisLin Cheng, Xian Tang, Li Liu, et al.
Mabs|May 10, 2023
Engaging natural killer cells for cancer therapy via NKG2D, CD16A and other receptorsKerry A Whalen, Kavya Rakhra, Naveen K Mehta, et al.
Mabs|April 9, 2021
Calculation of therapeutic antibody viscosity with coarse-grained models, hydrodynamic calculations and machine learning-based parametersPin-Kuang Lai, James W Swan, Bernhardt L Trout
Mabs|July 14, 2020
Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chainJoschka Bauer, Sven Mathias, Sebastian Kube, et al.
Mabs|April 26, 2021
A platform-agnostic, function first-based antibody discovery strategy using plasmid-free mammalian expression of antibodiesRuijun Zhang, Ponraj Prabakaran, Xiaocong Yu, et al.
Mabs|April 27, 2021
N-terminal selective conjugation method widens the therapeutic window of antibody-drug conjugates by improving tolerability and stabilityMin Ji Ko, Daehae Song, Juhee Kim, et al.
Mabs|May 15, 2023
Izokibep: Preclinical development and first-in-human study of a novel IL-17A neutralizing Affibody molecule in patients with plaque psoriasisSusanne Klint, Joachim Feldwisch, Lindvi Gudmundsdotter, et al.
Mabs|April 26, 2012
Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface displayChristian Votsmeier, Hanna Plittersdorf, Oliver Hesse, et al.
Mabs|April 26, 2012
Monoclonal antibodies: longitudinal prescribing information analysis of hypersensitivity reactionsKonstantin Kleyman, Debra S Weintraub
Pageof 184